Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy

Title:Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy

Volume: 20 Issue: 14

Author(s): Jiyang Li, Guangqiang Li and Wenqing Xu

Affiliation:

Keywords: Antitumor drugs, cancer therapy, cyclic peptide, drug discovery, epigenetic regulation, histone deacetylase, hdac isoforms, histone deacetylase inhibitors, hybrid compounds, multi-targeted inhibitor.

Abstract: Histone deacetylases are able to catalyze the hydrolysis of N-acetyl lysine residues of histones which package chromosomal DNA. Therefore they play an important role in mediating gene expression and cell proliferation. HDAC inhibitors have not only shown promise as antiparasitic, antineurodegenerative, antirheumatologic agents and immunosuppressant, but as potent anticancer agents by inducing cell cycle arrest, differentiation and apoptosis. This review highlights recent development in design, synthesis and biological evaluation of HDAC inhibitors for cancer therapy.

Cite this article as:

Li Jiyang, Li Guangqiang and Xu Wenqing, Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy, Current Medicinal Chemistry 2013; 20(14) . https://dx.doi.org/10.2174/0929867311320140005